Can Kanvas Biosciences turn microbiome replacement into a maternal health intervention?
Maternal EED lacks scalable therapies. Kanvas Biosciences now faces the harder test: proving microbiome replacement can work where need is greatest.
Can Vedanta Biosciences turn microbiome therapeutics into a real prevention strategy for recurrent CDI and resistant infections?
Vedanta Biosciences unveiled VE303 and VE707 data at ESCMID 2026. Read why the microbiome strategy matters for CDI and resistant infections.
Vedanta Biosciences keeps VE303 Phase 3 trial on track as interim review clears futility bar
Vedanta Biosciences kept VE303 Phase 3 on track after interim review. Read what this means for recurrent C. difficile treatment and microbiome drug development.
Why MaaT Pharma’s MaaT013 survival signal could reshape refractory GI-aGvHD treatment debate
MaaT Pharma’s MaaT013 posted pivotal Phase 3 GI-aGvHD data. Read what it could mean for EMA approval, adoption, and microbiome therapeutics.